Seeking Alpha

Seeking Alpha Portfolio App for iPad

Smith On Stocks

Smith On Stocks picture

Smith On Stocks

Profile

1,314 Followers

Send Message

View as an RSS Feed

View Smith On Stocks' Articles BY TICKER:

Antares: Reiteration Of My Buy Recommendation
on Thu, May 16 • PFE, TEVA, ATRS • 16 Comments
Neuralstem: Update On ALS Trial Could Be A Catalyst For The Stock
on Thu, May 16 • CUR • 2 Comments
Trius Therapeutics: New, Positive Dimension For Investment Outlook
on Mon, May 13 • CBST, TEVA, TSRX • 5 Comments
SmithOnStocks Opines On Recent Biotech News
on Mon, May 13 • APPA.OB, CADX, CUR • 8 Comments
ImmunoCellular Therapeutics: Marching Toward Top Line Data For ICT-107 In Q4 2013
on Fri, May 10 • IMUC • 10 Comments
InSite Vision: An Over-looked Company With 2 Interesting Drug Candidates And An Upcoming Catalyst
on Fri, May 10 • INSV.OB • Comment!
Transcept: Throwing In The Towel On Intermezzo
on Thu, May 9 • TSPT • 3 Comments
Northwest Biotherapeutics: Moving DC Vax-L Rapidly Forward And Starting DC Vax Direct Trials
on Tue, May 7 • DNDN, IMUC, NWBO • 61 Comments
Neuralstem: Anticipating More Efficacy Data From ALS Trial And Update On New Clinical Trials
on Tue, May 7 • CUR • 9 Comments
Cadence Pharmaceuticals: Ofirmev Launch Is Strong; Resolution Of Patent Issues Could Be Soon
on Mon, May 6 • CADX • Comment!
A.P. Pharma: Management Change Is A Positive For The Stock
on Fri, May 3 • APPA.OB • 5 Comments
Discovery Laboratories: Still Another Delay In The Surfaxin Launch
on Mon, Apr 15 • DSCO • 4 Comments
Cytokinetics: Key Issues For Beginning Phase III For Omecamtiv Mecarbil In Congestive Heart Failure
on Thu, Apr 11 • CYTK • 4 Comments
Trius: Clinical Trials Show Important Differentiation Of Tedizolid From Zyvox
on Tue, Apr 9 • TSRX • 13 Comments
Repligen Promises To Be A Cash Flow Machine
on Tue, Apr 2 • RGEN • 6 Comments
InSite Vision Concludes Royalty Deal On Besivance That Extends Cash Runway
on Tue, Apr 2 • INSV.OB, SWKH.OB • 1 Comment
A.P. Pharma Receives Complete Response Letter On APF530
on Thu, Mar 28 • APPA.OB • 21 Comments
ImmunoCellular Therapeutics: A Close Look At Key Issues For The Ongoing Phase II Trial Of ICT-107
on Wed, Mar 27 • NWBO, DNDN, IMUC • 39 Comments
Cytokinetics: Critical Phase IIb Data Is Upcoming In 2013 For Omecamtiv Mecarbil And Tirasemtiv
on Mon, Mar 25 • CYTK • 9 Comments
Discovery Laboratories: The Surfaxin Launch And Beyond
on Thu, Mar 21 • DSCO • 5 Comments
InSite Vision: Positive Phase III Trial Results For BromSite Reduces Much Of Downside Risk In The Stock
on Tue, Mar 19 • INSV.OB • 4 Comments
NovaBay: Topline Data From 2 Phase IIb Trials Presents Asymmetric Investment Opportunity
on Mon, Mar 18 • NBY • 4 Comments
Trius: Topline Data From Second Phase III Trial Of Tedizolid Is Imminent
on Mon, Mar 18 • CBST, DRTX, MDCO • 8 Comments
Cadence: Potential Near-Term Catalyst For The Stock
on Mon, Mar 11 • PRGO, CADX • 9 Comments
Northwest Biotherapeutics: My Rationale For Having A Buy Recommendation
on Mon, Feb 25 • DNDN, IMUC, NWBO • 37 Comments
Northwest Biotherapeutics: A Critique Of Adam Feuerstein Of TheStreet's Recent Analysis
on Tue, Feb 19 • IMUC, NWBO • 103 Comments
Transcept: The Prescription Trend Watch For Intermezzo Is On
on Thu, Feb 14 • TSPT • 9 Comments
Discovery Laboratories: Innovative Financing Is A Catalyst To Buy The Stock
on Thu, Feb 14 • DSCO • 11 Comments
Athersys: The Coming Year Will Define MultiStem, Its Adult Stem Cell Product
on Fri, Feb 8 • ARNA, AZN, CUR • 19 Comments
Sangamo: Paradigm-Shifting Approach To Gene Altering Leads To Unique Product Opportunities
on Fri, Jan 25 • SGMO • 18 Comments
A.P. Pharma: PDUFA Date On APF530 Looms And I Am A Buyer
on Fri, Jan 25 • APPA.OB • 48 Comments
In This Put-Up-Or-Shut-Up Year, MELA Sciences Should Succeed With Its Launch Of MelaFind
on Thu, Jan 24 • MELA • 31 Comments